Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Tissue Engineering and Regenerative Medicine Workshop Held in Kobe
December 19, 2005
- Korosho Proposes Direction for FY2006 NHI Pricing System Reform
December 19, 2005
- Requirements for DPC Hospitals Proposed by Korosho
December 19, 2005
- (Proposed) Direction for FY2006 NHI Pricing System Reform
December 19, 2005
- Pollinosis Much More Common in Boys Under 10 Years of Age
December 19, 2005
- Korosho's Reform Proposal Would Weaken Industry: Mr Crenshaw of PhRMA
December 19, 2005
- Airborne Cedar Pollen Levels Should Be Lower in 2006
December 19, 2005
- Long-listed Drugs' NHI Price Reductions to Negatively Affect State Finances: OPIR
December 19, 2005
- JSCPT Annual Assembly Held in Beppu
December 19, 2005
- EU Directive Effective in Improving Both Speed and Quality: QTJ
December 19, 2005
- R＆D NEWS IN BRIEF
December 19, 2005
- OPINION
December 19, 2005
- SYNPOSIUM
December 19, 2005
- SELF-MEDICATION NEWS IN BRIEF
December 19, 2005
- JPA Criticizes Gov't Framework for HC Reform
December 19, 2005
- Aska Pharm. to Promote Lipidil, Expand Generic Business: President Yamaguchi
December 19, 2005
- REGULATORY NEWS IN BRIEF
December 19, 2005
- Aiming at Global Top 10: Astellas
December 19, 2005
- President & CEO Stephen J. Ubl Meets Japanese Stakeholders: AdvaMed
December 19, 2005
- Pegintron, Rebetol Show Strong Growth in Japan: Schering-Plough
December 19, 2005
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…